ConforMIS Inc (NASDAQ:CFMS) major shareholder Archon Capital Management Llc sold 151,022 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $3.76, for a total transaction of $567,842.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Archon Capital Management Llc also recently made the following trade(s):
- On Tuesday, July 9th, Archon Capital Management Llc sold 279,293 shares of ConforMIS stock. The stock was sold at an average price of $3.77, for a total transaction of $1,052,934.61.
Shares of ConforMIS stock traded down $0.08 during midday trading on Thursday, reaching $3.73. 921,707 shares of the company’s stock traded hands, compared to its average volume of 1,400,302. The stock has a market capitalization of $256.51 million, a P/E ratio of -5.04 and a beta of 2.31. The firm has a 50 day moving average of $3.99. The company has a debt-to-equity ratio of 0.64, a quick ratio of 2.33 and a current ratio of 3.00. ConforMIS Inc has a 52 week low of $0.36 and a 52 week high of $4.83.
ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). The business had revenue of $20.64 million for the quarter, compared to the consensus estimate of $20.11 million. ConforMIS had a negative net margin of 42.90% and a negative return on equity of 97.85%. As a group, research analysts expect that ConforMIS Inc will post -0.43 EPS for the current year.
CFMS has been the subject of a number of research analyst reports. ValuEngine upgraded shares of Vistra Energy from a “hold” rating to a “buy” rating in a research report on Wednesday, July 3rd. Zacks Investment Research upgraded shares of HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. BidaskClub downgraded shares of Xperi from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 19th. BTIG Research raised their price target on shares of Yum! Brands to $114.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Finally, Oppenheimer cut their price target on shares of Littelfuse from $215.00 to $210.00 and set an “outperform” rating on the stock in a report on Thursday, May 2nd. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $3.40.
Several institutional investors have recently added to or reduced their stakes in the company. Spark Investment Management LLC raised its holdings in shares of ConforMIS by 172.2% during the 1st quarter. Spark Investment Management LLC now owns 500,000 shares of the medical instruments supplier’s stock valued at $1,440,000 after purchasing an additional 316,300 shares in the last quarter. Altrinsic Global Advisors LLC raised its holdings in shares of ConforMIS by 11.7% during the 1st quarter. Altrinsic Global Advisors LLC now owns 478,942 shares of the medical instruments supplier’s stock valued at $1,379,000 after purchasing an additional 50,000 shares in the last quarter. Tibra Equities Europe Ltd bought a new position in shares of ConforMIS during the 1st quarter valued at $381,000. Acadian Asset Management LLC raised its holdings in shares of ConforMIS by 26.0% during the 4th quarter. Acadian Asset Management LLC now owns 127,166 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 26,202 shares in the last quarter. Finally, Creative Planning raised its holdings in shares of ConforMIS by 133.8% during the 1st quarter. Creative Planning now owns 116,922 shares of the medical instruments supplier’s stock valued at $337,000 after purchasing an additional 66,922 shares in the last quarter. Institutional investors and hedge funds own 34.11% of the company’s stock.
ConforMIS Company Profile
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Featured Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.